In collaboration with Innodia, the ATIC network is leading IMPACT, the trial of a new medication (IMCY-0098), determining whether it can preserve pancreas function in people with newly diagnosed type 1 diabetes.

When type 1 diabetes is first diagnosed, the pancreas is still able to make small amounts of insulin, which helps control glucose levels. Preserving pancreas function can make glucose control easier and decrease the need to use replacement insulin.

This clinical trial is seeking participants aged between 18 and 45 years who have been diagnosed with type 1 diabetes in the past nine weeks.

For more information about IMPACT, click here.